AstraZeneca’s (AZN) Imfinzi has been approved in the European Union for the treatment of adult patients with resectable muscle-invasive bladder cancer in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radicalcystectomy, the company announced.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Summit Therapeutics Stock (SMMT) Jumps 8% on Talks of $15B Licensing Deal with AstraZeneca
- Biotech Alert: Searches spiking for these stocks today
- AstraZeneca’s Anifrolumab Study: A Potential Game-Changer for Inflammatory Myopathies
- AstraZeneca’s New Study on Asthma Biologics in China: Market Insights
- AstraZeneca’s Phase I Study on AZD5004: A Potential Market Game-Changer?